Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05965700 · ClinicalTrials.gov registry record · Phase 1
NVG-291 in Spinal Cord Injury Subjects
A Phase 1 study of Spinal Cord Injuries and Chronic Spinal Cord Injury, sponsored by NervGen Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05965700 is a Phase 1 study of Spinal Cord Injuries and Chronic Spinal Cord Injury that is actively recruiting participants, run by NervGen Pharma. The registered enrollment target is 40 participants, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05965700, a Phase 1 study of Spinal Cord Injuries and Chronic Spinal Cord Injury, is actively recruiting participants, sponsored by NervGen Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects
Conditions Studied
Interventions
- DRUG NVG-291
Study Locations (1)
Illinois
- Shirley Ryan AbilityLab - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-08 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05965700
The ClinicalTrials.gov registry entry for NCT05965700 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (34% lower). The listed sponsor is NervGen Pharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 1 intervention - of which NVG-291 is the first listed.
NCT05965700 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05965700 about?
NCT05965700 is a clinical study titled "NVG-291 in Spinal Cord Injury Subjects". A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects
What is the current status of trial NCT05965700?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-08-08. Estimated completion is 2026-04.
What conditions does trial NCT05965700 study?
This clinical trial studies the following conditions: Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury.
What interventions are being tested in trial NCT05965700?
The interventions under investigation include: NVG-291 (DRUG).
Who is sponsoring clinical trial NCT05965700?
This trial is sponsored by NervGen Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05965700 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injuries
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria
RECRUITING · Phase 1
-
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
RECRUITING · Phase 1
-
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
RECRUITING · Phase 1
-
Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacological Agents for Chronic Spinal Cord Injury (SCI)
COMPLETED · Phase 1
-
Improving Functioning in Persons With Chronic Pain Post-SCI Through Virtual Classroom Education
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.